Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
Immunotherapy is increasingly used in the treatment of multiple myeloma (MM). Monoclonal antibodies (mAbs) are safe and effective ways to elicit immunotherapeutic responses. In 2015, daratumumab has become the first mAb approved by the Food and Drug Administration for clinical use in MM and, in the...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/21/8192 |
| _version_ | 1797549084922347520 |
|---|---|
| author | Mattia D’Agostino Salvatore Innorcia Mario Boccadoro Sara Bringhen |
| author_facet | Mattia D’Agostino Salvatore Innorcia Mario Boccadoro Sara Bringhen |
| author_sort | Mattia D’Agostino |
| collection | DOAJ |
| description | Immunotherapy is increasingly used in the treatment of multiple myeloma (MM). Monoclonal antibodies (mAbs) are safe and effective ways to elicit immunotherapeutic responses. In 2015, daratumumab has become the first mAb approved by the Food and Drug Administration for clinical use in MM and, in the last 5 years, a lot of clinical and preclinical research has been done to optimize the use of this drug class. Currently, mAbs have already become part of standard-of-care combinations for the treatment of relapsed/refractory MM and very soon they will also be used in the frontline setting. The success of simple mAbs (‘naked mAbs’) prompted the development of new types of molecules. Antibody–drug conjugates (ADCs) are tumor-targeting mAbs that release a cytotoxic payload into the tumor cells upon antigen binding in order to destroy them. Bispecific antibodies (BiAbs) are mAbs simultaneously targeting a tumor-associated antigen and an immune cell-associated antigen in order to redirect the immune cell cytotoxicity against the tumor cell. These different constructs produced solid preclinical data and promising clinical data in phase I/II trials. The aim of this review article is to summarize all the recent developments in the field, including data on naked mAbs, ADCs and BiAbs. |
| first_indexed | 2024-03-10T15:09:38Z |
| format | Article |
| id | doaj.art-131196bdbf13441e9a5a4bd500ffba26 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T15:09:38Z |
| publishDate | 2020-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-131196bdbf13441e9a5a4bd500ffba262023-11-20T19:27:39ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-11-012121819210.3390/ijms21218192Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come TrueMattia D’Agostino0Salvatore Innorcia1Mario Boccadoro2Sara Bringhen3Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, 10126 Torino, ItalyMyeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, 10126 Torino, ItalyMyeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, 10126 Torino, ItalyMyeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, 10126 Torino, ItalyImmunotherapy is increasingly used in the treatment of multiple myeloma (MM). Monoclonal antibodies (mAbs) are safe and effective ways to elicit immunotherapeutic responses. In 2015, daratumumab has become the first mAb approved by the Food and Drug Administration for clinical use in MM and, in the last 5 years, a lot of clinical and preclinical research has been done to optimize the use of this drug class. Currently, mAbs have already become part of standard-of-care combinations for the treatment of relapsed/refractory MM and very soon they will also be used in the frontline setting. The success of simple mAbs (‘naked mAbs’) prompted the development of new types of molecules. Antibody–drug conjugates (ADCs) are tumor-targeting mAbs that release a cytotoxic payload into the tumor cells upon antigen binding in order to destroy them. Bispecific antibodies (BiAbs) are mAbs simultaneously targeting a tumor-associated antigen and an immune cell-associated antigen in order to redirect the immune cell cytotoxicity against the tumor cell. These different constructs produced solid preclinical data and promising clinical data in phase I/II trials. The aim of this review article is to summarize all the recent developments in the field, including data on naked mAbs, ADCs and BiAbs.https://www.mdpi.com/1422-0067/21/21/8192multiple myelomaimmunotherapymonoclonal antibodiesantibody–drug conjugatesbispecific antibodies |
| spellingShingle | Mattia D’Agostino Salvatore Innorcia Mario Boccadoro Sara Bringhen Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True International Journal of Molecular Sciences multiple myeloma immunotherapy monoclonal antibodies antibody–drug conjugates bispecific antibodies |
| title | Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True |
| title_full | Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True |
| title_fullStr | Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True |
| title_full_unstemmed | Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True |
| title_short | Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True |
| title_sort | monoclonal antibodies to treat multiple myeloma a dream come true |
| topic | multiple myeloma immunotherapy monoclonal antibodies antibody–drug conjugates bispecific antibodies |
| url | https://www.mdpi.com/1422-0067/21/21/8192 |
| work_keys_str_mv | AT mattiadagostino monoclonalantibodiestotreatmultiplemyelomaadreamcometrue AT salvatoreinnorcia monoclonalantibodiestotreatmultiplemyelomaadreamcometrue AT marioboccadoro monoclonalantibodiestotreatmultiplemyelomaadreamcometrue AT sarabringhen monoclonalantibodiestotreatmultiplemyelomaadreamcometrue |